MIPS #450 Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast Cancer

2025 measure specifications changes from 2024 highlighted below.

Coding changes and updates in Practice Insights are pending.

MEASURE DESCRIPTION

Percentage of patients aged 18 to 70 with stage I (T1c) – III HER2 positive breast cancer for whom appropriate treatment is initiated.

Relevance to Value Based Care

Clinical studies have shown that the administration of Trastuzumab or biosimilar significantly improves overall survival in patients with high-risk HER2 positive breast cancer.

 Numerator

Patients whose adjuvant treatment course includes both chemotherapy and HER2-targeted therapy

 Denominator

All breast cancer patients aged 18 to 70 with pathologic stage I (T1c) – III HER2 positive breast cancer diagnosed between July 1st of the previous performance period through June 30th of the current performance period-targeted therapy. 

Exclusion/Exceptions

• Pregnancy

• Inbound after initiation of treatment

• Medical or patient reason for not administering HER2-targeted therapy

Telehealth included: No

Scoring

1 - 7 points, 10 points for 100% performance percentage

 RESOURCES